Compound, pharmaceutical composition comprising same, and use thereof

A compound of formula (0) and its derivatives are used in pharmaceutical compositions to address the inadequacies of existing treatments for oxidative stress and inflammation, offering therapeutic efficacy against these conditions.

HK40135786APending Publication Date: 2026-07-31SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124785
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-14
Filing Date
2026-06-12
Publication Date
2026-07-31

AI Technical Summary

Technical Problem

Current pharmaceutical compositions lack effective compounds for treating specific diseases or conditions, particularly those involving oxidative stress and inflammation, which are not adequately addressed by existing treatments.

Method used

A compound of formula (0) or its derivatives, including stereoisomers, tautomers, geometrical isomers, enantiomers, diastereomers, racemic mixtures, polymorphs, solvates, hydrates, N-oxides, isotopically labeled compounds, esters, prodrugs, or pharmaceutically acceptable salts, are developed for use in pharmaceutical compositions targeting oxidative stress and inflammation.

Benefits of technology

The compound effectively targets oxidative stress and inflammation, providing a therapeutic benefit in treating related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present application provides a compound represented by formula (0), or a stereoisomer thereof, or a tautomer thereof, or a geometric isomer thereof, or an enantiomer thereof, or a diastereoisomer thereof, or a racemate thereof, or a polymorphic substance thereof, or a solvate thereof, or a hydrate thereof, or an N-oxide thereof, or an isotope labeled compound thereof, or a metabolite thereof, or an ester thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof;
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480034479.2 (22) Application Date 2024.07.12 (66) Domestic Priority Data 202310866584.X 2023.07.14 CN (85) PCT International Application Entering National Phase Date 2025.11.24 (86) PCT International Application Application Data PCT / CN2024 / 105066 2024.07.12 (87) PCT International Application Publication Data WO2025 / 016287 ZH 2025.01.23 (71) Applicant Shenzhen Zhongge Biotechnology Co., Ltd. Address 518017, Guangdong Province, China, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, 1st Floor, 289 Digital Peninsula (72) Inventors: Cao Bin, Zhao Liyu, Dou Guosheng, Lu Sizhu, Xie Dewei, Zhang Qihua, Wang Shaohui, Chen Bin, Zhang Peiyu (74) Patent Agency: China Council for the Promotion of International Trade Patent & Trademark Office Co., Ltd. 11038 Patent Attorney: Wang Na (51) Int.Cl. C07D 241 / 12 (2006.01) C07D 213 / 74 (2006.01) A61K 31 / 165 (2006.01) C07D 231 / 14 (2006.01) C07D 237 / 10 (2006.01) C07D 261 / 08 (2006.01) C07D 277 / 32 (2006.01) C07D 307 / 56 (2006.01) (54) Title of Invention: A compound, a pharmaceutical composition comprising the same, and uses thereof (57) Abstract: This application provides a compound of formula (0), or a stereoisomer thereof, a tautomer thereof, a geometrical isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemic mixture thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, an N-oxide thereof, an isotopically labeled compound thereof, a metabolite thereof, an ester thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof: CN 121263408 A 2026.01.02 CN 1 21 26 34 08 A